



# BEBPA 2022 US Bioassay Conference

21-24 March 2022

*6th Annual US Bioassay Conference*


**Audience Survey**




# Welcome & Introduction

By: Lauren Little

# i.1 How many BEBPA Conferences have you attended?



## i.2 What type of organization do you work for?




### i.3 What Part of the Organization do you work in?




### i.4 What type of products do you work with?


*(Check all that apply)*



### i.5 What type of assays do you develop? *(Check all that apply)*





i.7 For a hybrid European Conference (in-person plus virtual login option), would you prefer to attend:





i.7 For a hybrid European Conference (in-person plus virtual login option), would you prefer to attend:







**Day 1**  
**Stages in the Lifecycle of Bioassays Session**

Session Chair: Lauren Little


# 1.1 Are you currently or have you ever attempted to change a potency release assay?




## 1.2 Have you ever had to request a potency specification change post approval/licensure?




### 1.3 Do you run more than one potency assay to release a commercial product?



# 1.4 What type of protocol do you use for assay transfer?



# 1.5 Do you have a multi-tiered reference system?







**Day 2**  
**Bioassays for Novel Cell-Based Therapeutics Session**  
**&**  
**Bioassays for COVID-19 Therapeutics Session**  
Session Chair: Kristin Clement




## 2.1 Do you work with cell therapy products?




## 2.2 Do you work with vaccine products?




## 2.3 Do you use DOE for your bioassay development and/or optimization?



## 2.4 If you work with a vaccine product what type of formulation does your product have?







**Day 3**  
**Automating Bioassays Session**  
**&**  
**Potency Assay Method Development-Case Studies Session**

Session Chair: Siân Estdale


### 3.1 Does your organization use liquid handling and laboratory robotics?



### 3.2 What is your personal experience with liquid handlers and laboratory robotics?




### 3.3 When setting up a Potency Release Assay, do you consider:







### 3.4 Do you use Frozen Ready-to-Use (FRTU) cells?




### 3.5 Do you use automation to create your cell banks?




### 3.6 Do you use a Controlled Rate Freezer (CRF)?



### 3.7 What size FRTU banks do you typically generate?





**Day 4**


**Ins and Outs of Calculating Reportable Values Session**

Session Chair: Nancy Niemuth


# 4.1 What do you consider your training to be?



## 4.2 Do you quote confidence intervals on ELISA / Relative Potency results?




### 4.3 Do your 'Goodness of Fit' tests fail when you think they shouldn't?







#### 4.4 If you use pseudo-replicates, do you average the replicate responses at each dose before analysis?



## 4.5 What is your background in bioassay?



## 4.6 What is your statistics background?



14  
12  
10  
8  
6  
4  
2  
0



the hypothesis is true.

the data result from random chance alone.

results as extreme, or more extreme, than observed would happen.

measures the importance or size of the effect.

\*4.7 A p-value is the probability that...  
(\*relates to 1st talk, Day 4)

**THANK YOU**

for attending BEBPA's  
2022 US Bioassay Conference

*We could not have done this without YOU!*